If scientists knew exactly what a breast cancer cell needs to spread, then they could stop the most deadly part of the disease: metastasis. New research from the University of North Carolina at Chapel Hill School of Medicine takes a step in that direction.
Carol Otey, Ph.D. and UNC colleagues reduced the ability of breast cancer cells to migrate by knocking down the expression of a protein called palladin.
They also found higher levels of palladin in four invasive breast cancer cell lines compared to four non-invasive cell lines.
"This study shows that palladin may play an important role in the metastasis of breast cancer cells as they move out of the tumor and into the blood vessels and lymphatics to spread throughout the body," said Otey, associate professor of cell and molecular physiology.
To conduct the study, the researchers grew breast cancer cells in an "invasion chamber," in which human tumor cells are placed in a plastic well that is inserted into a larger well. Cells will attempt to move to the bottom of the chamber because it's baited with growth factors that cells find attractive. But first the cells have to migrate through a filter coated with a layer of artificial connective tissue. "The cells have to migrate through that and have to degrade it," Otey said. "It's a useful model system that mimics what happens in the body."
The study results appeared in the Nov. 3, 2008, online edition of the journal Oncogene.
Most women would never die from breast cancer if the cancer cells couldn't metastasize to the brain and bone marrow, Otey said. "To really make breast cancer a treatable disease, we have to be able to find a way to prevent or reduce the amount of metastasis."
"Now that we see palladin is expressed mostly in invasive cells, it raises the question as to whether it might be useful as a prognostic marker," Otey said. "Maybe someday doctors could test for the presence of palladin to identify patients who have the most aggressive tumors, then give those patients personalized, more aggressive treatment."
The study benefited from the collaboration between Otey's cell and molecular physiology lab and Dr. Hong Jin ("H.J.") Kim's surgical oncology lab. "I learned a lot from H.J. about the challenges that clinicians face as they try to optimize the treatment of each breast cancer patient," Otey said.
Otey has been investigating palladin's role in cell movement since she discovered and named it in 2000.
Next she will examine a variety of samples of human tumors from a UNC tumor bank, to find out if the tumors from patients who had worse outcomes and more aggressive cancers contain higher levels of palladin.
Source: University of North Carolina School of Medicine
Related stories:
Novel prostate cancer vaccine taking aim at cancer cell 'sweet spot'
Molecules of sugar sitting on the surface of cancer cells are keys to the development of a new vaccine aimed at both treating and stopping the spread of certain types of cancers called carcinomas, which include prostate, breast, ovarian and lung, among others. Armed with a new two-year grant for $600,000 from the Gateway for Cancer Research, an Illinois-based philanthropic foundation, immunologist Alessandra Franco, M.D., Ph.D., and her co-workers at the Moores Cancer Center at the University of California, San Diego are hoping to develop a low-cost immunotherapy for prostate carcinoma that may also have use against a variety of other carcinomas as well.
Absence of CLP protein can be indicative of oral cancer
Human calmodulin-like protein (CLP) is found in many cell types including breast, thyroid, prostate, kidney, and skin. The protein can regulate many cell activities and has a highly specific expression. Gaining an understanding about the expression of CLP in oral epithelial cells and its possible downregulation (or lack of production) in cancer may be a potentially valuable marker in early detection of oral cancer. A new study in the
Journal of Prosthodontics found that CLP is expressed in normal human oral muscosal cells and that downregulation of this protein may be an indicator of malignancy or cancer.
Researchers uncover 'relocation' plan of metastatic cancer cells
Few things are as tiresome as house hunting and moving. Unfortunately, metastatic cancer cells have the relocation process down pat. Tripping nimbly from one abode to another, these migrating cancer cells often prove far more deadly than the original tumor. Although little has been known about how these rogue cells choose where to put down roots, researchers at the Stanford University School of Medicine have now learned just how nefarious they are.
Team finds breast cancer gene linked to disease spread
A team of researchers at Princeton University and The Cancer Institute of New Jersey has identified a long-sought gene that is fatefully switched on in 30 to 40 percent of all breast cancer patients, spreading the disease, resisting traditional chemotherapies and eventually leading to death.
Dormant cancer cells rely on cellular self-cannibalization to survive
A single tumor-suppressing gene is a key to understanding, and perhaps killing, dormant ovarian cancer cells that persist after initial treatment only to reawaken years later, researchers at The University of Texas M. D. Anderson Cancer Center report in the December
Journal of Clinical Investigation.
Grape-seed extract kills laboratory leukemia cells, proving value of natural compounds
An extract from grape seeds forces laboratory leukemia cells to commit cell suicide, according to researchers from the University of Kentucky. They found that within 24 hours, 76 percent of leukemia cells had died after being exposed to the extract.
Young blood fights cancer
"New blood" can revitalize a company or a sports team. Recent research by Tel Aviv University finds that young blood does a body good as well, especially when it comes to fighting cancer.
How to enhance non-thermal effects of ultrasound
In recent years HIFU has been widely used for the treatment of solid tumors, such as liver tumor, bone tumor, and breast cancer. The mechanism for therapeutic actions of HIFU includes thermal effects and non-thermal effects with the latter dominated by cavitational effects. Adjusting acoustic parameters of pulsed high intensity focused ultrasound (PHIFU) can control thermal effects and non-thermal effects; short duty cycle and high intensity favors the occurrence of cavitation. Ultrasound contrast agent (UCA) can enhance cavitational effects. Lesions caused by non-thermal effects have characteristic pathological changes quite different from those of thermal lesions.